Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

STIP1/HOP promotes the formation of cytotoxic α-synuclein oligomers.

Molecular neurodegeneration advances·2026
Same author

An automated workflow for quantifying the formation of synuclein aggregates in human dopaminergic neurons.

Methods (San Diego, Calif.)·2026
Same author

N-terminal acetylation reduces synuclein pathology in models of Parkinson's disease.

Neurobiology of disease·2026
Same author

Prefrontal parvalbumin neurons mediate working memory in a task demand-dependent manner.

Nature communications·2026
Same author

From adaptive to maladaptive myelination: White matter dynamics in cognition and neurologic disorders.

Neuroscience and biobehavioral reviews·2026
Same author

Cell type transcriptomic modules reveal shared molecular mechanisms in Alzheimer's and Parkinson's disease.

GigaScience·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Sriram Jayabal1, Ali R Khan1, Edward A Fon2

  • 1Western University, London, ON, Canada.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

TRIDENT enhances neurodegenerative disease drug development by integrating advanced human-relevant models and open science principles. This approach aims to improve pre-clinical trial success rates and accelerate the discovery of effective therapies.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Translational Medicine
  • Drug Discovery

Background:

  • Neurodegenerative diseases like Alzheimer's and Parkinson's are complex, poorly understood, and pose a significant global health and economic burden.
  • Current central nervous system (CNS) drug development faces high clinical trial failure rates (92%) due to issues like non-human-relevant measures and poor reproducibility.
  • There is a critical need for improved pre-clinical approaches to enhance the predictive validity of drug candidates for neurodegenerative disorders.

Purpose of the Study:

  • To introduce the TRanslational Initiative to DE-risk NeuroTherapeutics (TRIDENT) platform, designed to address critical gaps in neurodegenerative disease pre-clinical evaluation.
  • To improve the predictive validity of pre-clinical to clinical outcomes in drug discovery for neurodegenerative conditions.
  • To foster inclusivity, collaboration, and reproducibility in pre-clinical research through open science principles.

Main Methods:

  • TRIDENT integrates human-induced pluripotent stem cells (iPSCs) and organoids, humanized mouse models, and marmoset models into a unified platform.
  • The platform utilizes human-relevant, touchscreen-based cognitive tasks in mice and marmosets, which are highly translatable to human cognition.
  • TRIDENT incorporates Sex-Based Analysis (SBA)+ and open science principles, with multi-site validation at McGill University, University of Toronto, and CAMH.

Main Results:

  • The TRIDENT platform offers a novel solution for developing effective neurodegenerative disease therapies.
  • It maximizes predictive validity, thereby de-risking the drug discovery and development process.
  • Current evaluations focus on compounds for alpha-synucleinopathies and Alzheimer's Disease to validate the platform's efficacy.

Conclusions:

  • TRIDENT is poised to revolutionize pre-clinical testing methodologies for neurodegenerative disorders.
  • The platform aims to make the drug discovery process more attractive to pharmaceutical and biotechnology industries.
  • This initiative is expected to accelerate the identification of effective cures and therapies for debilitating neurodegenerative conditions.